4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms (2024)
- Authors:
- USP affiliated authors: PEREIRA, MAURÍCIO DOS SANTOS - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; GUIMARAES, ELAINE APARECIDA DEL BEL BELLUZ - FORP ; VANDERLEI, LEONARDO CALAÇA ARRUDA - FMRP
- Unidades: FMRP; FORP
- DOI: 10.1016/j.neuropharm.2024.109926
- Subjects: ANTI-INFLAMATÓRIOS; CANABINOIDES; ANIMAIS DE LABORATÓRIO; DOENÇA DE PARKINSON; GLUTAMATOS
- Keywords: CB1; CB2; Glutamate; HU-910; Neuroinflammation; Parkinson's disease
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Neuropharmacology
- ISSN: 0028-3908
- Volume/Número/Paginação/Ano: v. 251, art. 109926, [15] p, 2024
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PEREIRA, Maurício dos Santos et al. 4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms. Neuropharmacology, v. 251, 2024Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2024.109926. Acesso em: 14 fev. 2026. -
APA
Pereira, M. dos S., Abreu, G. H. D. de, Vanderlei, L. C. A., Raisman-Vozari, R., Guimarães, F. S., Lu, H. -C., et al. (2024). 4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms. Neuropharmacology, 251. doi:10.1016/j.neuropharm.2024.109926 -
NLM
Pereira M dos S, Abreu GHD de, Vanderlei LCA, Raisman-Vozari R, Guimarães FS, Lu H-C, Michel PP, Del Bel EA. 4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms [Internet]. Neuropharmacology. 2024 ; 251[citado 2026 fev. 14 ] Available from: https://doi.org/10.1016/j.neuropharm.2024.109926 -
Vancouver
Pereira M dos S, Abreu GHD de, Vanderlei LCA, Raisman-Vozari R, Guimarães FS, Lu H-C, Michel PP, Del Bel EA. 4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms [Internet]. Neuropharmacology. 2024 ; 251[citado 2026 fev. 14 ] Available from: https://doi.org/10.1016/j.neuropharm.2024.109926 - Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-κB-dependent signaling and glucose consumption
- The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of Parkinson's disease
- CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease
- Rifampicin and its derivative Rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by α-Synuclein fibrillary aggregates
- Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia
- The two synthetic cannabinoid compounds 4′-F-CBD and HU-910 efficiently restrain inflammatory responses of brain microglia and astrocytes
- Caracterização das células NG2-glia durante o curso temporal de lesão nigroestriatal dopaminérgica em camundongos hemiparkinsonianos
- The role of nitric oxide in salivary gland hypertrophy induced by isoproterenol
Informações sobre o DOI: 10.1016/j.neuropharm.2024.109926 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
